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SynthesisAbstract Some novel 6,8-diiodo-2-methyl-3-substituted-quinazolin-4(3H)-ones bearing sulfon-
amide derivatives (4–11) were synthesized in good yields and evaluated for their possible antibacte-
rial, anti-inﬂammatory activities and acute toxicity. The structures of the synthesized compounds
were conﬁrmed on the basis of their spectral data and elemental analysis. Their antibacterial activ-
ities were evaluated by the agar well diffusion method while their anti-inﬂammatory activities were
evaluated by the carrageenan-induced hind paw edema test. All the tested compounds showed con-
siderable antibacterial activities and high to moderate anti-inﬂammatory activities that last for 12 h
compared to ibuprofen. All the tested compounds showed no toxic symptoms or mortality rates
24 h post-administration at tested anti-inﬂammatory doses. In addition, LD50 for all tested com-
pounds was higher than that for ibuprofen implying their good safety margin. The obtained results
showed that the most active compounds could be useful as a template for future design, modiﬁca-
tion and investigation to produce more active analogs.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
There is a strong relationship between bacterial infection and
inﬂammation (Sy et al., 2011). Bacterial infection often pro-
duces pain and inﬂammation. Inﬂammation remains a com-
mon with poorly controlled clinical problem which can be
life threatening in extreme form of allergy, autoimmune dis-
eases and rejection of transplanted organs (Gounon and
Huerre, 1996). The treatment options which can be used for
inﬂammatory diseases are unsatisfactory and complicated
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Figure 1 Similarities between reported compounds as antibac-
terial, anti-inﬂammatory and target compounds (4–11).
158 M. F. Zayed, M. H. Hassandue to their lack of efﬁcacy and adverse effect proﬁle. It seemed
worthwhile to look for candidates acting onmore than one path-
way involved in inﬂammatory conditions (Bot et al., 2011).
Quinazolin-4-one ring system has been consistently re-
warded as a promising molecule because of its broad spectrum
of pharmaceutical activities like antihistaminic (Lemura et al.,
1989), anti inﬂammatory (Amin et al., 2010), antibacterial
(Kini and Grover, 2006), antidiabetic (Ram et al., 2003), anti-
cancer (Abbas et al., 2012), antifungal (Liu et al., 2006),
anthelmintics (Connolly et al., 2005) and antiviral activities
(Dinakaran et al., 2003). In addition to that, anti-inﬂamma-
tory quinazolines possess remarkable anti-inﬂammatory activ-
ity through inhibition of tumor necrosis factor-alpha (TNF-a)
and interleukin-6 (IL-6) (Rajan et al., 2010).
On the other hand, sulfonamide derivatives have been reported
to possess signiﬁcant antibacterial activities through competitive
inhibition of dihydropteroate synthetase enzyme (DHPS) which
is involved in folate synthesis (Skold, 2000). Moreover, some sul-
fonamides work as ant-inﬂammatory drugs like celecoxib which
works as a COX-2 inhibitor (Gassani et al., 2010) and acetazola-
mide which works by diuretic mechanism (Jaiswal et al., 2004).
On light of these ﬁndings, we planned to prepare the target com-
pounds as hybrid molecules. These molecules contain the quinaz-
olinone ring system and fused with sulfonamide derivatives to
form a group of compounds resembling and collecting both fea-
tures of nitrogen heterocyclic moiety and sulfonamide moiety. In
addition, iodine atoms exist at 6th and 8th positions from quinaz-
oline nucleus. Iodine was selected because it has received consider-
able attention in organic synthesis due to its high tolerance to air
and moisture, low-cost, nontoxic nature and ready availability.
Presence of iodine increases the lipophilicity of the molecules, the
surface of contact, the absorption and the distribution (Laznicek
et al., 1985; Yanming et al., 2003).
1.1. Rationale of the study
A literature survey revealed that the presence of quinazoline
moiety, which can undergo substitution at the heteroatom or
the distal aromatic ring, is a necessary requirement for the anti-
bacterial and anti-inﬂammatory activities such as compounds
[A] (Kini and Grover, 2006), [B] (Ali et al., 2010) and [C] (Pan-
neerselvam et al., 2009). Moreover, quinazoline derivatives
with the appropriate substituent mainly amine or substituted
amine at 4th position and either halogen or electron rich substi-
tuent at 6th or 8th position are known to promote against bac-
teria and inﬂammation (Tiwari et al., 2006). In view of the
previous rationale, it was thought worthwhile to study the ef-
fects of two pharmacophoric moieties like quinazolinone and
sulfonamide in a single molecule on the antibacterial and
anti-inﬂammatory activities. The target compounds have been
designed to contain different substituents with different elec-
tronic environments. As shown in Scheme 1, these substituents
joined to the ﬁxed moiety (3) start with hydrogen from sulfanil-
amide in compound (4), acetamide from sulfacetamide in com-
pound (5), benzamide from sulfabenzamide in compound (6),
pyridine from sulfapyridine in compound (7), pyrimidine from
sulfadiazine in compound (8), 5-methylisoxazole from sulfa-
methoxazole in compound (9), 4,6-dimethylpyrimidin from sul-
famethazine in compound (10) and 3,4-dimethyl-1,2-oxazole
from sulfafurazole in compound (11). These varied substituents
allow us to study the effect of hydrophilic and hydrophobicchanges on the biological activity of the target compounds.
Fig. 1 represents the similarities between the reported antibac-
terial and anti-inﬂammatory quinazolinones and our designed
compounds.
2. Materials and methods
2.1. Chemistry
The tested compounds were analyzed at the Analytical Center,
College of Science, Cairo University, Egypt. All melting points
were measured on a Grifﬁn melting point apparatus (Grifﬁn)
and are uncorrected. The Infrared spectra were recorded as
KBr disks on a Nicolet IR 200 (Thermo Fisher Scientiﬁc).
The 1HNMR and 13CNMR spectra were run using TMS as
an internal standard (Sigma–Aldrich) on Varian Mercury
VXr-300 NMR (Varian). Mass spectra were obtained on a
JEOL-SX-102 instrument using electron impact ionization.
Elemental analyses (C, H, N) were performed on a Perkin–El-
mer 240C analyzer (Perkin–Elmer). All compounds were with-
in ±0.4% of the theoretical values. All chemicals used for
synthesis were purchased from (Sigma–Aldrich).
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The synthetic strategy to prepare the target compounds (4–11)
is depicted in Scheme 1: it includes two simple reactions, ﬁrst
one is the acetylation/benzoylation followed by the ring clo-
sure reaction for 2-amino-3,5-diiodobenzoic acid (1). Com-
pound (1) when reﬂuxed with acetic anhydride for one hour
converted into benzoxazinone. This reaction afforded quanti-
tative yield of 6,8-diiodo-2-methyl-4H-benzo[d][1,3]oxazin-4-
one (2). Second reaction is a nucleophilic displacement reac-
tion for the oxygen of benzoxazinone with the nitrogen of
the amino group upon treating with sulfonamides. The second
reaction was done by reﬂuxing compound (2) with the appro-
priate sulfonamide in dry conditions for six hours to give
sulfonamide derivatives of 6,8-diiodo-2-methyl-quinazolinone
(4–11) in variable yields between 62% and 76%.
2.3. Pharmacology
2.3.1. Animals
The animals were procured from the Animal House Center,
College of Pharmacy, King Abdulaziz University, Saudi Ara-
bia, and were maintained in a colony cages at 25 ± 2 C, rel-
ative humidity of 45–55%, under 12 h light and dark cycles;
they were fed standard animal feed. All animals were acclima-
tized for a week before use. The protocol adopted for the
experimentation of animals was approved by the Institutional
Animal Ethics Committee (approval No: 409/432). All the
experiments were carried out according to the respective inter-
nationally valid guidelines.
2.3.2. Biological screening
All the newly synthesized compounds (4–11) were screened to
evaluate their antibacterial and anti-inﬂammatory activities
and acute toxicity. The antibacterial activity was performed
by the agar well diffusion method while the anti-inﬂammatory
activity was evaluated by the carrageen an induced rat Paw
edema method using ibuprofen as a reference drug. The re-
sponse of all the compounds to antibacterial activity is good
however, some of the compounds showed promising anti-
inﬂammatory activity. The other remaining compounds
showed moderate anti-inﬂammatory activity. No toxic symp-
toms or mortality rates were observed 24 h post administrationTable 1 Antibacterial activity of tested compounds (4–11).
Compound ID Gram positive strains Gram negative strains
S. aureus S. epidermis P. aeruginosa E. coli
4 20 21 18 22
5 17 19 20 20
6 14 18 14 17
7 18 20 15 20
8 19 17 21 19
9 15 16 21 16
10 13 15 20 21
11 19 18 21 19
Streptomycin
(standard)
21 23 24 29
Inhibitory zone diameters in mm; conc of standard 50 lg/ml,
compounds 100 lg/ml.implying their good safety margin. The details of activity re-
sults are outlined below.
2.3.3. Antibacterial activity
Antibacterial activity of all the test compounds was deter-
mined by agar well diffusion method (Waynae, 1997) which
is recommended by the National Committee for Clinical Lab-
oratory Standards (NCCLS) against two kinds of Gram posi-
tive micro organisms Staphylococcus aureus (MTCC 96) and
Staphylococcus epidermis (MTCC 435) and two kinds of
Gram negative micro organisms Pseudomonas aeruginosa
(MTCC 741), and Escherichia coli (MTCC443) at 100 lg/mL
concentration using dimethylsulfoxide (DMSO) as a solvent.
The bacteria were sub-cultured on Mueller Hinton agar med-
ium. Streptomycin was used as a standard antibacterial under
similar conditions at a concentration of 50 lg/mL for compar-
ison while solvent control was also maintained under similar
conditions. The results of antibacterial screening are outlined
in Table 1.
2.3.4. Acute toxicity
Toxicological studies of the synthesized compounds were per-
formed using (LD50) which is the dose that will kill 50% of the
animal population within 24 h post treatment with the test
substance. The toxicity test was performed using standard
method in mice and rats (Ishii and Yoshikawa, 1993; Ecobi-
chon, 1997; Upmanyu et al., 2011). When there is no informa-
tion on a substance to be tested, for animal welfare reasons, it
is recommended to use the starting dose of 300 mg/kg body
weight. The animals were given the lowest dose of 300 mg/kg
of the compounds at the ﬁrst instance. Then the animals were
observed for three days. They were treated orally with different
doses of tested compounds (400, 600, 800, 1000, and 2000 mg/
kg). The animals were then observed for 24 h for any behav-
ioral effects such as nervousness, excitement, dullness, in-coor-
dination or even death. Results for LD50 were calculated and
are reported in Table 2.
2.3.5. Anti-inﬂammatory activity
Anti-inﬂammatory activity of all the test compounds was
determined according to the reported method (Winter et al.,
1962; Vogel, 2007) by carrageenan-induced hind paw edema
test using ibuprofen as a standard drug. Brieﬂy, Male orTable 2 Acute toxicity studies in mice and rats.
Compound No LD50(mg/kg)
Mice Rats
4 1015 950
5 974 844
6 1300 1245
7 1136 1020
8 1035 985
9 1554 1470
10 1633 1580
11 1670 1513
Ibuprofen (standard) 750 650
LD50: dose that kills 50% of animals within 24 h after drug
administration.
Table 3 Anti-inﬂammatory activity and duration of tested compounds at 50 mg/kg using carrageen an induced rat
paw edema method.
Compound ID Percent protection
3 h 6 h 12 h
4 39.14 ± 0.02*,** 56.26 ± 0.04*,** 51.41 ± 0.24*,**
5 41.75 ± 0.65*,** 62.83 ± 0.61*,** 58.15 ± 0.06*,**
6 27.2 ± 0.01*,** 38.15 ± 0.04*,** 36.41 ± 0.25*,**
7 36.58 ± 0.47*,** 44.62 ± 0.09*,** 49.71 ± 0.34*,**
8 27.92 ± 0.3*,** 41.14 ± 0.07*,** 39.61 ± 0.67*,**
9 23.27 ± 0.71*,** 31.34 ± 0.06*,** 35.78 ± 0.86*,**
10 20.56±.03*,** 27.47 ± 0.03*,** 34.58 ± 0.43*,**
11 19.25 ± 0.71*,** 28.16 ± 0.02*,** 25.52 ± 0.6*,**
Ibuprofen (standard) 68.12 ± 0.61* 69.91 ± 0.74* 67.54 ± 0.07*
*,** Signiﬁcant difference from negative control and ibuprofen (standard), respectively at P< 0.0001, using Tukey’s test as
post ANOVA test.
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tion, the rats received 5 ml of water by stomach tube (con-
trols), standard ibuprofen (25, 50 and 100 mg/kg), or test
compounds (25, 50, 100 and 200 mg/kg) suspended in the same
volume. One hour later, the rats were challenged by a subcuta-
neous injection of 0.1 ml of 1% solution of carrageenan (Sig-
ma–Aldrich) into the plantar side of the left hind paw. The
thickness of dorso-ventral diameter of each rat was measured
using a pair of dial thickness gauge calipers accurate to
0.001 cm3 (Progressive Trading Corporation) 3, 6 and 12 h
after induction of inﬂammation. The increase of paw volume
after 3, 6 and 12 h was calculated as percentage compared with
the volume measured immediately after injection of the irritant
for each animal (0 h). Effectively treated animals show much
less edema. The percentage of anti-inﬂammatory activity (%
inhibition of inﬂammation) was calculated according to the
following equation:
% inhibition ¼ ðLc Lt=LcÞ  100
Lt is the mean increase in paw thickness in rats treated with the
tested compounds and Lc is the mean increase in paw thick-
ness in control group.
Evaluation: The difference at the various time intervals
gives some hints for the duration of the anti-inﬂammatory ef-
fect for each compound as reported in Table 3. Doses thatTable 4 ED50 and Relative potency of tested compounds to
Ibuprofen at 6 h.
Compound ID ED50 (mg/kg) Relative potency
4 60 0.66
5 54 0.74
6 90 0.44
7 69 0.58
8 75 0.53
9 105 0.38
10 120 0.33
11 117 0.34
Ibuprofen (standard) 40 1.00
ED50 is the dose required to induce 50% inhibition of rat paw
edema (50% anti-inﬂammatory effect).
ED50 was calculated using instate program by plotting results at all
doses levels; Ibuprofen was tested at a dose range from 25 to
100 mg/kg and tested compounds from 25 to 200 mg/kg.exhibited 50% protection in addition to the relative potencies
of the test compounds to ibuprofen were recorded for compar-
isons and are shown in Table 4.
3. Results
Antibacterial assay of all the test compounds (4–11) showed
good activities against both of Gram positive bacteria and
Gram negative bacteria. These activities were ranged from
61.91% up to 95.23% from the activity of the standard. The
activity data generated are tabulated in Table 1. The anti-
inﬂammatory screening showed that compounds (6, 7, 8, 9,
10 and 11) were considered to have moderate anti-inﬂamma-
tory activity however, compounds (4 and 5) showed consider-
able inhibition as shown in Tables 3 and 4. No toxic
symptoms or mortality rates were observed 24 h post-adminis-
tration at all suggested therapeutic doses however, the LD50 for
most of tested compounds is much higher than that reported
for ibuprofen. Concerning other actions, compounds 7, 8 and
11 induced urination while compounds 4, 5 and 6 induced seda-
tion, calmness, muscle relaxation and decreased respiration.4. Discussion
Inspection of the chemical structure of the target compounds
suggested that target compounds could be divided into two
subunits: the quinazolinone part and the sulfonamide part
(Fig. 1). The two parts have been reported to have signiﬁcant
broad spectrum of antibacterial activities which might
contribute to the good results obtained from testing them
as antibacterial agents. Moreover, substitution of the distal
aromatic ring from quinazolinone moiety with iodine at 6th
and 8th positions might also helped in obtaining such good
results.
For the anti-inﬂammatory activity, compounds with ali-
phatic side chain (4) and (5) were more active than that with
aromatic one. Compound (5), the most active compound
among all the test compounds, contains aliphatic side chain.
The relative potency of this compound was 74% of the refer-
ence’s potency, as shown in Table 4. Pyridine containing com-
pound (7) was more active than those with pyrimidine or
oxazole instead. Within the pyrimidine and oxazole deriva-
tives, dimethylated derivatives (10) and (11) were less active
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results of acute toxicity test which have been done to all test
compounds indicated to their good safety margin. Although
the title compounds exhibited potent antibacterial and anti-
inﬂammatory actions, moderate anti-inﬂammatory activity
was found. Hence, necessary structural modiﬁcations are
planned in the future study to increase the anti-inﬂammatory
activity. In general, the present study showed that compound
(5) was the most active compound with combined ability to in-
hibit bacterial infection and inﬂammation. This compound
could therefore serve as a lead molecule for further modiﬁca-
tion to obtain clinically useful antibacterial and anti-inﬂamma-
tory agents.
5. Conclusion
We have synthesized and tested some novel 6,8-diiodo-2-
methyl-3-substituted-quinazolin-4(3H)-ones derivatives for
their antibacterial and anti-inﬂammatory activities. All com-
pounds induced signiﬁcant antibacterial activity. Two com-
pounds showed promising anti-inﬂammatory activity while
the other ﬁve compounds showed moderate anti-inﬂammatory
activity. All Compounds were tested for acute toxicity and
showed good safety margin.
6. Experimental
6.1. Chemistry
6.1.1. 6,8-Diiodo-2-methyl-4H-benzo[d][1,3]oxazin-4-one (2)
It was prepared by reﬂuxing (3,88 gm, 0.01 mol) of 2-amino-
3,5-diiodobenzoic acid (1) with the appropriate amount of
acetic anhydride for one hour. The residue obtained was evap-
orated till complete dryness, left to cool, washed with petro-
leum ether many times, collected, ﬁltered and dried well in
the absence of moisture.
Yield 85%, mp: 185–187 C; 1HNMR (DMSO-d6): d 1.21
(s, 3H, CH3) 7.21–8.19 (m, 2H, Ar–H).
13C NMR (DMSO-
d6): d 24.23, 82, 90.5, 118.5, 138.2, 149.6, 150, 154.1, 158.
Anal. Calcd. for C9H5I2NO2 (412.84): C, 26.18; H, 1.22;
N, 3.39. Found C, 26.32; H, 1.01; N, 3.74. MS (EI) m/z
413.8 [M + 1].
6.1.2. General method for preparation of test compounds (4–11)
They were prepared in a conical ﬂask by mixing (0.01 mol,
4.13 gm) of compound (2) with the appropriate amount
(0.01 mol) of sulfonamide derivatives in 100 ml dry pyridine,
reﬂuxed for six hours, cooled then treated with few amounts
of 10% hydrochloric acid and poured onto crushed ice. The
obtained crystals were collected by ﬁltration and re-crystallized
from ethanol or glacial acetic acid. The melting points for all
synthesized compounds were above 300 C.
6.1.3. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-
yl)benzenesulfonamide (4)
Yield 73%, 1HNMR (DMSO-d6): d 2.26 (s, 3H, CH3), 5.3 (s,
2H, NH2), 6.96–7.77 (m, 6H, Ar–H).
13C NMR (DMSO-d6):
d 48.2, 82.3, 91.4, 120.5, 121.9, 125, 192.7, 134.5, 142.7,
145.1, 149.4, 157.2, 164. Anal. Calcd. for C15H11I2N3O3S
(566.88): C, 31.77; H, 1.95; N, 7.41. Found C, 31.61; H,
1.81; N, 7.29. MS (EI) m/z 567.8 [M + 1].6.1.4. N-(4-(6,8-diiodo-7-methyl-4-oxoquinazolin-3(4H)-
yl)phenylsulfonyl)acetamide (5)
Yield 70%, 1HNMR (DMSO-d6): d 2.21 (s, 3H, CH3), 2.41(s,
3H, CH3), 7.01–8.12 (m, 6H, Ar–H), 8.4 (s, 1H, NH)
13C
NMR (DMSO-d6): d 24.5, 48, 85.4, 93.7, 123.5, 128, 135,
137.5, 141.7, 149.2, 159.2, 166, 175.4. Anal. Calcd. for
C17H13I2N3O4S (608.87): C, 33.52; H, 2.15; N, 6.90. Found
C, 33.43; H, 1.98; N, 7.12. MS (EI) m/z 609.8 [M + 1].
6.1.5. N-(4-(6,8-diiodo-7-methyl-4-oxoquinazolin-3(4H)-
yl)phenylsulfonyl)benzamide (6)
Yield 76%, 1HNMR (DMSO-d6): d 2.33 (s, 3H, CH3), 6.71–
8.26 (m, 11H, Ar–H), 8.37 (s, 1H, NH) 13C NMR (DMSO-
d6): d 48.51, 84.9, 95.3, 121.5, 123.2, 127.5, 128.3, 129, 132.6,
134.3, 135, 137.6, 140.7, 146.2, 154.9, 163, 172.2. Anal. Calcd.
for C22H15I2N3O4S (670.89): C, 39.36; H, 2.25; N, 6.26. Found
C, 39.51; H, 2.47; N, 6.47. MS (EI) m/z 671.8 [M + 1].
6.1.6. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-
(pyridin-2-yl)benzenesulfonamide (7)
Yield 68%, 1HNMR (DMSO-d6): d 2.42 (s, 3H, CH3), 6.92–
8.15 (m, 10H, Ar–H), 8.27 (s, 1H, NH) 13C NMR (DMSO-
d6): d 48.71, 82.9, 93.2, 112.2, 120.4, 122.2, 128.3, 129, 136.6,
139, 140.7, 141.2, 147.1, 148, 152.4, 155.9, 162. Anal. Calcd.
for C20H14I2N4O3S (643.89): C, 37.29; H, 2.19; N, 8.70. Found
C, 37.12; H, 2.37; N, 8.93. MS (EI) m/z 644.8 [M + 1].
6.1.7. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-
(pyrimidin-2-yl)benzenesulfonamide (8)
Yield 65%, 1HNMR (DMSO-d6): d 2.35 (s, 3H, CH3), 7.02–
8.35 (m, 9H, Ar–H), 8.41 (s, 1H, NH) 13C NMR (DMSO-
d6): d 48.15, 81.2, 114, 122, 126.4, 128, 129.4, 138, 140.7,
146.2, 154, 158, 160.7, 170. Anal. Calcd. for C19H13I2N5O3S
(644.88): C, 35.37; H, 2.03; N, 10.85. Found C, 35.64; H,
2.33; N, 10.75. MS (EI) m/z 645.8 [M + 1].
6.1.8. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-
(5-methylisoxazol-3-yl)benzenesulfonamide (9)
Yield 70%, 1HNMR (DMSO-d6): d 2.32 (s, 3H, CH3), 2.46 (s,
3H, CH3), 7.21–8.14 (m, 7H, Ar–H), 8.31 (s, 1H, NH)
13C
NMR (DMSO-d6): d 14.5, 48.57, 85.2, 92, 96, 122, 124.6,
129.3, 136, 136.2, 140, 146.8, 150, 154, 156.5, 160, 171.3. Anal.
Calcd. for C19H14I2N4O4S (647.88): C, 35.20; H, 2.18; N, 8.64.
Found C, 35.16; H, 2.41; N, 8.54. MS (EI) m/z 648.8 [M + 1].
6.1.9. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-
(4,6-dimethlpyrimidin-2-yl)benzenesulfonamide (10)
Yield 66%, 1HNMR (DMSO-d6): d 2.41 (s, 3H, CH3), 2.52 (s,
6H, 2CH3), 6.91–7.98 (m, 7H, Ar–H), 8.21 (s, 1H, NH)
13C
NMR (DMSO-d6): d 28, 49, 86.4, 95.1, 112, 121, 126.6, 130,
138, 138.2, 144, 148.2, 158, 162.4, 164, 175.3. Anal. Calcd.
for C21H17I2N5O3S (672.91): C, 37.46; H, 2.55; N, 10.40.
Found C, 37.29; H, 2.77; N, 10.54. MS (EI) m/z 673.9 [M + 1].
6.1.10. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-
(3,4-dimethlisoxazol-5-yl)benzenesulfonamide (11)
Yield 62%, 1HNMR (DMSO-d6): d 2.31 (s, 6H, 2CH3), 2.43 (s,
3H, CH3) 7.03–8.17 (m, 6H, Ar–H), 8.36 (s, 1H, NH)
13C
NMR (DMSO-d6): d 7.5, 10.8, 48.92, 86, 93.1, 102, 123,
125.2, 129.5, 136, 136.4, 140, 146.2, 149, 156.1, 157, 159.4,
162 M. F. Zayed, M. H. Hassan162. Anal. Calcd. for C20H16I2N4O4S (661.90): C, 36.27; H,
2.44; N, 8.46. Found C, 36.49; H, 2.65; N, 8.61. MS (EI) m/z
662.9 [M+ 1].
6.2. Statistical analysis
Data obtained were expressed as means. Statistical difference
between the treated and the control groups was evaluated by
One Way Analysis of Varian (ANOVA) followed by the Tu-
key’s test as a post ANOVA multiple comparison test (Sigma
Stat version 3; SPSS Inc.) to determine the statistical signiﬁ-
cance. A P value <0.05 was considered statistically signiﬁcant.
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